Deciphera Pharmaceuticals, Inc. (DCPH) Analysts See $-0.71 EPS

July 14, 2018 - By Kyle Williams

Analysts expect Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) to report $-0.71 EPS on August, 14.After having $-0.66 EPS previously, Deciphera Pharmaceuticals, Inc.’s analysts see 7.58 % EPS growth. The stock decreased 2.29% or $0.88 during the last trading session, reaching $37.56. About 135,847 shares traded. Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company has market cap of $1.41 billion. The firm develops DCC-2618, a pan-KIT and pan-PDGFRa inhibitor for the treatment of gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. It currently has negative earnings. It is also developing immunokinase inhibitors comprising DCC-3014 for treatment of solid tumors and hematologic malignancies; and Rebastinib to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors.

More notable recent Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) news were published by: which released: “Benzinga’s Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares” on June 19, 2018, also with their article: “Andreas Halvorsen Takes Stake in Eidos Therapeutics” published on July 03, 2018, published: “The Market In 5 Minutes: Trade Tensions Intensify, ZTE Rebuked, Housing Starts And More” on June 19, 2018. More interesting news about Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) were released by: and their article: “Deciphera Pharma Hit With Sell-Side Downgrade On Valuation After 50% Gain” published on June 19, 2018 as well as‘s news article titled: “50 Biggest Movers From Friday” with publication date: June 25, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.